<DOC>
	<DOCNO>NCT01957826</DOCNO>
	<brief_summary>The purpose study assess safety , feasibility efficacy transendocardial injection bone marrow-derived mesenchymal stem cell ( MSCs ) patient dilate idiopathic cardiomyopathy .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Idiopathic Dilated Cardiomyopathy</brief_title>
	<detailed_description>Chronic congestive heart failure ( CHF ) public health problem entail high rate morbidity mortality , enormous cost health system worldwide . In United States 5 million people live CHF , year 60.000 people reach terminal phase disease , mortality rate 70-80 % two year . Although first cause CHF develop country atherosclerotic coronary artery disease ( CAD ) , dilate idiopathic cardiomyopathy ( DCM ) represent almost half case newly diagnose CHF . Treatment CHF include pharmacological non-pharmacological strategy , include implantable cardioverter defibrillator , cardiac resynchronization therapy heart transplantation . Despite advance , CHF prognosis remain poor . Cardiac stem cell therapy emerge ten year ago new hope CHF patient . Although extensive evidence benefit stem cell therapy cardiovascular disease refers ischemic heart disease ( CAD ) , initial experience stem cell condition DCM encouraging . This randomized clinical trial include 70 patient DCM , leave ventricular ejection fraction ( LVEF ) 20 % 45 % , symptomatic New York Heart Association ( NYHA ) functional class II-III/IV . In first-in-man pilot phase , 10 patient treated transendocardial injection bone marrow-derived MSCs cardiac catheterization NOGA XPTM mapping leave ventricle . A Data Safety Monitoring Board ( DSMB ) analyse safety feasibility first phase trial , 60 patient randomized receive MSCs placebo ( ratio 3:1 ) . Primary objective include safety feasibility variable , secondary objective include efficacy variable . All patient study complete cardiac imaging protocol include : electrocardiography , echocardiography , treadmill test oxygen consumption , holter , laboratory analysis , magnetic resonance imaging ( MRI ) , single photon emission compute tomography ( SPECT ) , electromechanical mapping ( NOGA XPTM ) quality life questionnaire .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>IIIII NYHA functional class , optimal medical therapy . LVEF ≥ 20 % ≤ 45 % echocardiography , SPECT leave ventriculogram one month prior enrollment . Anterior wall thickness ≥ 8 mm echocardiography MRI one month prior enrollment . Idiopathic DCM diagnosis ( excluded CAD , valvular heart disease , cardiac toxic drug , tachyarrhythmias , metabolic disease , systemic disease , infectious disease ) six month prior enrollment . Patients reject heart transplantation discuss Heart Team respective centre , document state reason exclusion keep medical record . Able exercise treadmill , MVO2 ≥ 12 ≤ 21 ml/Kg/min . Hemodynamic stability ( blood pressure &gt; 100/40 mmHg , heart rate &lt; 110 bpm oxygen saturation &gt; 95 % ) . Negative pregnancy test woman . Signed informed consent Evidence secondary dilate cardiomyopathy cause : CAD , valvular heart disease , cardiac toxic drug , tachyarrhythmias , metabolic disease , systemic disease , infectious disease , myocarditis postpartum ventricular dysfunction . Permanent atrial fibrillation . Candidates ICD CRT device . Patients theses device enrol device implant least 6 month inclusion , noresponse observe CRT . Candidates heart transplantation surgery anticipate next 2 year . Left ventricular thrombus echocardiography , MRI leave ventriculogram . Peripheral artery disease preclude cardiac catheterization 8 Fr sheath . . Anterior wall thickness &lt; 8 mm echocardiography MRI one month prior enrollment . Chronic renal failure ( creatinine &gt; 2,5 mg/dL ) . I IV NYHA functional class . Cardiogenic shock define systolic blood pressure &lt; 90 mmHg response fluid , &lt; 100 mmHg inotropes without bradycardia . Previous history drug abuse ( alcohol , etc… ) . Acute chronic infectious disease ( include B/C hepatitis HIV ) . Pregnancy childbearing period . MRI contraindication : pacemaker , ICD , metalic prosthesis , etc . Bleeding coagulation disorder ( INR &gt; 2 without anticoagulation treatment ) . Cancer history 5 year prior enrollment . Life expectancy less 1 year . Any disease condition investigator find decisive exclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>mesenchymal</keyword>
	<keyword>stem cell</keyword>
	<keyword>transendocardial injection</keyword>
	<keyword>dilate idiopathic cardiomyopathy</keyword>
	<keyword>idiopathic cardiomyopathy</keyword>
</DOC>